May 2024
Extended Data from Gilead’s PBC Program Strengthens Case Ahead of FDA Ruling
Gilead, PBC Program, FDA Decision, Long-term Data, Primary Biliary Cholangitis
Progentos Secures $65 Million for Groundbreaking Remyelination Therapy in Multiple Sclerosis Treatment
Progentos, funding, remyelination therapy, multiple sclerosis, MS treatment, clinical trials, neurodegenerative diseases, nervous system repair, biotechnology.
Tezspire Clinical Trials by AstraZeneca and Amgen: Empowering Patient Choice in COPD Treatment
Tezspire, AstraZeneca, Amgen, clinical trials, COPD, patient choice, pivotal studies, treatment.
Hims & Hers Expands Weight-Loss Solutions with GLP-1 Injections
Hims & Hers, GLP-1 injections, weight-loss, telehealth, prescription medication, obesity treatment, metabolic health
FDA Revokes Accelerated Approval of Helsinn’s Cancer Drug at Company’s Request
FDA, Helsinn, accelerated approval, cancer drug, company request, drug withdrawal, regulatory decision, clinical trials, patient safety.
AstraZeneca Ordered to Pay Pfizer Over $107 Million in Tagrisso Patent Infringement Case
AstraZeneca, Pfizer, Tagrisso, patent infringement, jury verdict, damages, lung cancer treatment
Translarna by PTC Therapeutics: Awaiting Another EU Regulatory Review for Muscular Dystrophy Treatment
PTC Therapeutics, Translarna, muscular dystrophy, EU review, regulatory approval, Duchenne muscular dystrophy (DMD), European Medicines Agency (EMA), ataluren, rare disease treatment.
Legislators Profit from Bill Restricting Chinese Biotech Firms
Congress, stock trading, China biotech ban, financial gain, legislative influence, conflict of interest.
Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine
Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.
Revolutionizing Drug Discovery: The Evolution from Target-Selective Design to AI-Powered Polypharmacology
Drug Discovery, Target-Selective Design, AI-Enabled Polypharmacology, Machine Learning, Systems Biology, Multi-Target Drugs, Personalized Medicine.